Cravens & Co Advisors’s Insmed INSM Stock Holding History

Cravens & Co Advisors’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,020	Closed	-$330K	–	72
2026 Q1	$330K	Hold	2,020	–	–	0.21%	55
2025 Q4	$331K	Hold	2,020	–	–	0.22%	50
2025 Q3	$291K	Buy	+2,020	New	+$247K	0.2%	50

Other funds holding INSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Cravens & Co Advisors's INSM Position: Q2 2026 in Review

Cravens & Co Advisors sold out of Insmed (INSM) in Q2 2026, closing a stake of 2,020 shares — an estimated $330K sold.

Cravens & Co Advisors first reported a position in INSM in Q3 2025 and held it in 3 quarters. The position peaked at $331K in Q4 2025. 665 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

Cravens & Co Advisors reported no remaining Insmed position as of Q2 2026 after selling out during the quarter.
Cravens & Co Advisors sold 2,020 Insmed shares in Q2 2026, an estimated $330K.
Cravens & Co Advisors first reported a position in Insmed in Q3 2025 and held it in 3 quarters.
Cravens & Co Advisors's Insmed position peaked at $331K in Q4 2025.
665 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on Cravens & Co Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.